CION Ameerpet
If a fine-needle aspiration (FNA) raised a suspicion of lymphoma, the usual next step is a whole-node biopsy. Here is why lymphoma is diagnosed on an intact lymph node — its architecture and its markers — not on a handful of aspirated cells.
When a lymph node stays enlarged and lymphoma is a possibility, the very first decision — which biopsy to do — shapes how quickly and how accurately you get a diagnosis. Many patients arrive at CION after a fine-needle aspiration (FNA) came back "inconclusive" or "suspicious", only to be told a second, bigger biopsy is needed. This page explains why that happens and how to get the right test the first time.
The short answer: lymphoma is not diagnosed on a few loose cells. It is diagnosed on the architecture of an intact lymph node — the way the cells are organised — together with a panel of tissue tests. An FNA cannot show that architecture, which is why an FNA is often not enough for lymphoma. An excisional (whole-node) biopsy can, which is why it is the preferred first test under both NCCN and ESMO guidelines.
For the wider picture of diagnosis and care, see the Lymphoma hub and our Lymphoma Treatment in Hyderabad page. If you already have an FNA report in hand, our team can advise on the right next biopsy.
International guidelines are explicit that a fine-needle aspiration is not sufficient for a reliable first-time diagnosis of lymphoma. NCCN and ESMO both recommend an excisional (or incisional) lymph node biopsy as the preferred procedure, because subtyping depends on assessing the intact node architecture alongside immunophenotyping — something a needle aspirate cannot provide. Where surgery is not feasible, multiple good-quality core needle biopsies are the accepted alternative. (Source: NCCN Clinical Practice Guidelines and ESMO Clinical Practice Guidelines for lymphoma.)
All three sample a lymph node — but they collect very different amounts of tissue, and that difference decides whether a lymphoma can be fully diagnosed and subtyped.
| Method | What is taken | Shows node architecture? | Role in lymphoma |
|---|---|---|---|
| FNA (fine-needle aspiration) | A few loose cells drawn through a thin needle | No | Usually not enough for a first diagnosis; useful for screening a node, checking infection, or confirming a known relapse |
| Core needle biopsy | Thin cylinders (cores) of solid tissue, often image-guided | Partly | Good alternative when a node is deep or surgery is risky; multiple cores can subtype many lymphomas |
| Excisional biopsy | The whole lymph node (or a large part of it) | Yes | Preferred first-line test; gives enough tissue for the full panel and the most reliable subtype |
The right choice varies by individual and by where the node sits; this table is a general guide. The final decision is made by your haematology and pathology team following NCCN and ESMO guidance.
A lymph node is not a bag of identical cells. Its internal structure carries much of the diagnostic information — which is lost the moment you only aspirate a few cells.
Pathologists look at whether a node's normal follicular pattern is preserved, partly effaced or completely replaced. That whole-node pattern is a major clue to the lymphoma subtype and to telling lymphoma apart from a benign, reactive node. An FNA removes the cells from that pattern, so the clue is lost.
Subtyping needs several tests run in parallel — immunohistochemistry, flow cytometry and sometimes molecular tests. A whole node provides enough material to complete all of them on the first attempt, avoiding a repeat procedure.
Because an FNA so often has to be followed by a bigger biopsy, going straight to the right test can mean one procedure instead of two — less delay, less anxiety and a faster path to a definite subtype and a plan.
The exact subtype decides how urgent treatment is and which approach is used. A whole-node diagnosis lets the subtype be identified confidently, so the plan discussed on our Treatment page is built on solid ground.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
If an FNA has left you without a clear answer, or you want to be sure the right biopsy is planned, CION's haematology team can review your findings and advise the next step.
An excisional biopsy is the surgical removal of an entire enlarged lymph node so a pathologist can examine it intact. It is a well-established, generally short procedure, and understanding the steps takes a lot of the worry out of it.
For a fuller walk-through of the procedure and what to expect afterwards, see Lymph node biopsy for lymphoma — what to expect.
An excisional biopsy is preferred, but it is not always the safest or most practical option. The choice is individualised.
When the suspicious node sits deep in the chest or abdomen, removing it surgically may carry more risk than benefit. Here an image-guided core needle biopsy — taking several cylinders of tissue under CT or ultrasound — is the accepted alternative. Multiple good cores can subtype many lymphomas, though occasionally the diagnosis still needs an excisional biopsy to be completed.
An FNA is quick and low-risk, so it has a genuine role: screening an accessible node to see if it looks suspicious, checking for infection or a different cancer that has spread to the node, or confirming a relapse of a lymphoma that was already fully characterised on an earlier whole-node biopsy. What it generally cannot do is establish a lymphoma subtype from scratch.
Whichever biopsy is chosen, it is part of a bigger picture that may include blood tests, imaging, and — for staging — a bone marrow biopsy and PET scanning read with the Deauville score. A raised LDH and features such as bulky disease also feed into the plan.
A whole-node sample lets the laboratory run every test that defines a lymphoma subtype — from immunohistochemistry markers (such as CD20, CD30 and CD3) to molecular tests for cell-of-origin and double-hit rearrangements (MYC and BCL2). These markers are precisely what separate one lymphoma from another and guide how urgently it needs treating. A fine-needle aspirate rarely yields enough tissue to complete this panel — another reason the whole node, not a few cells, is the goal. (Source: WHO classification of lymphoid tumours; NCCN and ESMO lymphoma guidelines.)
Once the tissue reaches the lab, the pathologist assembles the findings into a report that names the lymphoma subtype and its key features. Understanding that report helps you follow the plan your team recommends.
At CION, biopsy coordination, the full tissue-testing panel, staging and treatment are managed by one team, so nothing falls through the gaps. Treatment itself — chemotherapy, antibody (immunotherapy) and targeted therapy, and radiation (IMRT) — is delivered directly; where a stem-cell transplant or CAR-T cell therapy is indicated, it is coordinated through accredited partner facilities. To meet the team, see our Best Lymphoma Doctors in Hyderabad and Best Lymphoma Hospital in Hyderabad pages.
Getting the biopsy right is not a formality — it changes outcomes, because the subtype guides the whole plan. Many lymphomas are highly treatable when diagnosed and classified accurately: published series report roughly 80–90% long-term survival for Hodgkin lymphoma and around 60–70% for diffuse large B-cell lymphoma, the most common aggressive non-Hodgkin type (figures per published NCCN- and ESMO-referenced series). These figures vary considerably by individual, subtype, stage and response — your own outlook can only be judged by your treating team.
A second opinion is especially worthwhile if an FNA was inconclusive, if no full subtyping panel was run, or before you commit to a treatment path. CION offers a dedicated free written second-opinion service. Request your free second opinion or call 18002028726.
Get a free written second opinion from CION's haematology team — especially valuable if an FNA did not give a clear subtype and you're deciding on the next biopsy.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.A fine-needle aspiration (FNA) collects only a small cluster of loose cells, not intact tissue. Diagnosing lymphoma depends on seeing how the lymph node is architecturally arranged — the pattern of the cells within the node — and on running a panel of tests on a solid tissue sample. An FNA cannot show that architecture, so it usually cannot tell the exact lymphoma subtype or reliably separate lymphoma from a reactive (benign) node. Both NCCN and ESMO guidelines state that FNA alone is inadequate for a first lymphoma diagnosis. This is the core reason lymphoma needs the whole node — see our lymph node biopsy guide.
An excisional biopsy is the surgical removal of an entire (or a large part of an) enlarged lymph node so a pathologist can examine the whole node intact. Because the complete node is available, the pathologist can study its architecture, run immunohistochemistry, flow cytometry and molecular tests, and pin down the exact lymphoma subtype. It is the preferred (gold-standard) first biopsy for a suspected lymphoma under NCCN and ESMO guidance. It is usually a short procedure done under local or general anaesthetic depending on the node's depth and location.
A whole node biopsy means the pathologist receives the entire lymph node rather than a few scraped cells or a thin core. This matters because lymphoma is diagnosed partly on the overall pattern of the node — whether the normal follicular structure is preserved, effaced or replaced. That pattern, combined with the cell markers, is what separates one lymphoma subtype from another and from benign conditions. A whole node gives enough tissue to complete every test on the first attempt, reducing the chance of a repeat procedure. Where a node cannot be fully removed, a generous core needle biopsy under image guidance is the next best option.
When a lymph node sits deep inside the chest or abdomen, or surgery would be risky, a core needle biopsy under CT or ultrasound guidance is often used. It removes thin cylinders of tissue — more than an FNA and enough to attempt subtyping in many cases — but less than a whole node. Guidelines accept multiple good-quality cores as a reasonable alternative when an excisional biopsy is not feasible. The trade-off is that a core sometimes cannot fully classify the lymphoma, and a repeat or excisional biopsy may still be needed. The choice is made case by case, weighing accessibility against the need for a complete diagnosis.
Yes, in specific situations. An FNA can be a quick, low-risk first step to check whether an enlarged node looks suspicious, to sample an easily accessible node, or to confirm a relapse of a lymphoma that has already been fully characterised on a previous whole-node biopsy. It can also help rule out infection or a different cancer that has spread to the node. What an FNA generally cannot do is make a reliable first-time lymphoma diagnosis or establish the subtype on its own. If your FNA raised a suspicion of lymphoma, the usual next step is an excisional or core biopsy — speak to a CION haematologist about the right test for your situation.
A lymphoma diagnosis is built from several tests on the biopsy tissue. The pathologist first studies the node architecture under the microscope, then runs immunohistochemistry to detect surface markers such as CD20, CD30, CD3 and others; flow cytometry and immunophenotyping to profile the cells; and, where needed, molecular and genetic tests for features like cell-of-origin or double-hit rearrangements (MYC, BCL2). The findings are assembled into your pathology report. Running this full panel needs enough tissue — which is exactly why a whole node, or generous cores, is preferred over an FNA.
A lymph node that is painless, firm, steadily enlarging over weeks, or larger than about 2 cm without an obvious infection deserves prompt assessment. Guidelines advise not delaying a diagnostic biopsy once lymphoma is genuinely suspected, because the subtype determines how urgently treatment is needed — some lymphomas are slow-growing while others move quickly. That said, an accurate whole-node diagnosis is worth doing properly rather than rushing an FNA that has to be repeated. At CION, a haematologist reviews your scan or examination findings and arranges the right biopsy quickly. Learn more on our Lymphoma Treatment in Hyderabad page.
Browse our complete guide to lymphoma — symptoms, diagnosis, Hodgkin and non-Hodgkin subtypes, treatment, genetics, prognosis, survivorship and cost. Tap any topic to read more.